Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s (NYSE:PFE) Xtandi (enzalutamide).
The data showed that Erleada (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).
Presented at the 6th European Congress of Oncology Pharmacy, the study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The analysis demonstrated patients with mCSPC who initiated Erleada as their first ARPI had a statistically ...
